AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) On 31 may announced the presentation of results from a first-in-human Phase 1 study of AV-203, AVEO’s ErbB3 (HER3) inhibitory antibody candidate. Among the results, the study established a recommended Phase 2 dose of AV-203, demonstrated good tolerability and promising early signs of activity, and reached the maximum planned dose of AV-203 monotherapy. AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) weekly performance is 27.27%. On last trading day company shares ended up $1.40. Analysts mean target price for the company is $1.67. AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) distance from 50-day simple moving average (SMA50) is 14.04%.
Arrowhead Research Corporation (NASDAQ:ARWR) a biopharmaceutical company developing targeted RNAi therapeutics is set to join the broad-market Russell 3000 Index when Russell Investments reconstitutes its comprehensive set of U.S. and global equity indexes on June 27 according to a preliminary list of additions posted June 13 on www.russell.com/indexes. Arrowhead Research Corp (NASDAQ:ARWR) shares advanced 8.84% in last trading session and ended the day on $13.42. ARWR return on assets is -47.50%.Arrowhead Research Corp (NASDAQ:ARWR) quarterly performance is -40.80%.
Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) on 10 June supplemented its April 29, 2014 definitive Proxy Statement previously furnished to stockholders in connection with its upcoming 2014 Annual Meeting of Stockholders to provide additional information in light of comments recently made by ISS Proxy Advisory Services. Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) shares moved up 7.00% in last trading session and was closed at $4.43, while trading in range of $4.10 – $4.45. Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) year to date (YTD) performance is -16.89%.
ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) on 23 may presented encouraging data on its oncology candidate Ad-RTS-IL-12 at the annual meeting of the American Society of Gene and Cell Therapy (:ASGCT). The company stated that Ad-RTS-IL-12 demonstrated potent anti-tumor and anti-cancer stem cell effects in glioma (brain cancer) preclinical and clinical studies. Reduction in tumor mass was observed with Ad-RTS-IL-12 arm as compared to existing treatment standards. Additionally, the candidate was found to prolong survival. ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) ended the last trading day at $4.27. Company weekly volatility is calculated as 5.67% and price to cash ratio as 7.12.ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) showed a positive weekly performance of 4.66%.
GTx, Inc. (NASDAQ:GTXI) on 2 June announced positive results from a Phase 2, proof-of-concept, open-label clinical study evaluating enobosarm (GTx-024), a selective androgen receptor modulator (SARM), for the treatment of patients with androgen receptor (AR) positive and estrogen receptor (ER) positive metastatic breast cancer who have previously responded to hormonal therapy. GTx, Inc. (NASDAQ:GTXI) weekly performance is 8.27%. On last trading day company shares ended up $1.44. Analysts mean target price for the company is $1.50. GTx, Inc. (NASDAQ:GTXI) distance from 50-day simple moving average (SMA50) is 1.75%.